On March 4, 2026, Antengene announced a global exclusive licensing agreement with UCB, granting UCB the global rights to develop, manufacture, and commercialize the CD19/CD3 bispecific antibody ATG-201, along with the transfer of related manufacturing technologies. ATG-201 was developed based on the AnTenGager™ platform, utilizing steric hindrance shielding technology to reduce the risk of cytokine release syndrome. Under the agreement, Antengene will receive an upfront payment of US$80 million and near-term milestone payments (US$60 million upfront + US$20 million conditional milestone payment), with the potential to receive subsequent milestone payments of up to over US$1.1 billion, as well as tiered royalties on future net sales. Antengene plans to submit clinical trial applications for ATG-201 in China and Australia in the first quarter of 2026 and, upon completion of the first-in-human (Phase I) clinical study, will transfer subsequent development responsibilities to UCB.